HSCS HEART TEST LABORATORIES INC

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) --  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October 15 to Thursday October 17, 2024.

Mr. Simpson is scheduled to participate in a fireside chat with analyst Allen Klee at 10:30 a.m. Eastern Time on Thursday, October 17th.

To sign up for the event please register at or .

About HeartSciences

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform. Working with clinical experts, HeartSciences ensures that all solutions are designed to work within existing clinical care pathways, making it easier for clinicians to use AI-ECG technology to improve their patient's care and lead to better outcomes. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test.

For more information, please visit: . X: .

Contacts:

HeartSciences

Gene Gephart

(US)



Investors

Gilmartin Group

Vivian Cervantes



EN
14/10/2024

Underlying

HSCSHEART TEST LABORATORIES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HEART TEST LABORATORIES INC

 PRESS RELEASE
Free
HSCS HEART TEST LABO...

University of West England Adopts HeartSciences’ MyoVista Insights™ Pl...

University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) --    (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the University of the West of England (“UWE”) has adopted the Company’s MyoVista Insights™ platform and MyoVista® wavECG™ device as its exclu...

February 5, 2026 1 EN
 PRESS RELEASE
Free
HSCS HEART TEST LABO...

Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed...

Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) --   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that Cibolo Rural Health Networks (“Cibolo Health”) has selected MyoVista Insights™ as its endorsed ECG management platform for independent hospitals within its high...

January 29, 2026 1 EN
 PRESS RELEASE
Free
HSCS HEART TEST LABO...

HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and...

HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal second quarter ended October 31, 2025 (“FQ2 2026”) and provided a business update. Second Quarter and Recent Highlights During the second quarter and subsequent period, the Compan...

December 15, 2025 1 EN
 PRESS RELEASE
Free
HSCS HEART TEST LABO...

HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ De...

HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) --   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced it has submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance. The MyoVista wavECG device is designed to provide conventional ECG functionality while serving as a platform capable of hostin...

December 15, 2025 1 EN
 PRESS RELEASE
Free
HSCS HEART TEST LABO...

HeartSciences Announces Major Upgrade to User Features of MyoVista Ins...

HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1 Version 1.1 Designed to Provide Best Usability of any ECG System Southlake, TX, Dec. 11, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced the commercial release of MyoVista Insights™ version 1.1, a major update that is built to provide the most usable ECG system and enhances clini...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch